Source-grounded facts extracted from Dogwood Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Dogwood Therapeutics, Inc. terminated Equity Distribution Agreement (effective 2026-01-09).
“On January 9, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) provided notice of its termination, effective January 9, 2026, of the Equity Distribution Agreement, dated November 28, 2025 (the “Northland Agreement")”
Dogwood Therapeutics, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at approximately $12.5 million (effective 2026-01-11).
“On January 11, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”)”
Dogwood Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-01-11).
“On January 11, 2026, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor”
Dogwood Therapeutics, Inc. entered into Purchase Agreement with a single institutional investor valued at approximately $12.5 million (effective 2026-01-11).
“On January 11, 2026, Dogwood Therapeutics, Inc., a Delaware corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor named therein (the “Investor”) pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Offering”) to the Investor 2,338,948 shares of common stock”
Dogwood Therapeutics, Inc.: Company filed a Certificate of Designation for Series A-2 Non-Voting Convertible Preferred Stock, establishing preferences, rights, and limitations including voting restrictions, dividend prohibition, conversion rights, and protective provisions (effective 2025-09-29).
“On September 29, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series A-2 Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the Serpin Registration Rights Agreement referenced in Item 1.01 above.”
Angela Walsh changed role as Chief Financial Officer at Dogwood Therapeutics, Inc..
“promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024”
Melvin Toh was appointed as Director at Dogwood Therapeutics, Inc..
“and Melvin Toh as a director of the Company”
Alan Yu was appointed as Director at Dogwood Therapeutics, Inc..
“appointed Alan Yu as a director of the Company”
Richard Burch resigned as Director at Dogwood Therapeutics, Inc..
“accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024”
Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $1.3 million, EPS $0.07 basic and diluted net loss per share.
“Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the first quarter ended March 31, 2024.”
Dogwood Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.
“May 1, 2024, we received another letter from Nasdaq informing us that our shares had failed to comply with the $1.00 minimum bid price required for continued listing. In accordance with the latest letter and established Nasdaq procedures, we have requested a hearing with Nasdaq, at which, we will seek to extend the period during which we will seek to regain compliance. Our request for such hearing has stayed the delisting of our common stock pending a Nasdaq hearings panel’s (the “Panel”) decision. We intend to present a plan to regain compliance to the Panel that includes a discussion of the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.